
Carvedilol
Carvedilol is one of the beta-blockers with the strongest survival evidence in heart failure: in large trials it cut deaths by about a third or more in people with a weak heart muscle, including severe heart failure, and it lowered deaths after a heart attack in people whose heart pumping was reduced. In a head-to-head trial it also lowered deaths more than immediate-release metoprolol tartrate. For supplements and drinks, the main concerns are energy drinks, which push blood pressure the other way; CBD, which blocks the CYP2D6 enzyme that clears carvedilol in lab studies; St. John's wort, which speeds the breakdown of many drugs; and celery products that add to blood pressure lowering.
Prescription medication: not a dietary supplement
This is an FDA-approved (or investigational) drug, not a supplement. It requires a prescription and medical supervision. The information below summarizes clinical-trial evidence for education only. It is not a recommendation to obtain or use it without a doctor.
Quick decision guide
May help most
Adults with chronic heart failure with reduced pumping strength, reduced heart function after a heart attack, or high blood pressure, treated and monitored by a prescriber
Common dosing range
Set by your prescriber and raised slowly. For heart failure, Coreg tablets start at 3.125 mg twice daily for 2 weeks and are increased step by step to as much as 25 mg twice daily; the Coreg CR capsule label starts at 10 mg once daily and goes up to 80 mg once daily
When to expect effects
Blood pressure falls within hours, and the label says the full blood pressure effect of a dose shows within 7 to 14 days. Survival benefit in heart failure trials appeared over months
Watch out for
Do not stop carvedilol suddenly: the label warns that abrupt stopping in people with heart artery disease has caused severe angina, heart attacks and dangerous heart rhythms, and says to taper over 1 to 2 weeks. It is contraindicated in asthma. Dizziness and fainting are most likely in the first hour after a dose when starting or raising it, so take it with food and avoid driving until you know how it affects you
What is it
Carvedilol is a prescription beta-blocker that also relaxes blood vessels, used for chronic heart failure, for reduced pumping strength of the heart after a heart attack, and for high blood pressure. It comes as Coreg and generic carvedilol tablets, taken twice a day, and as Coreg CR (carvedilol phosphate) extended-release capsules, taken once a day. Unlike atenolol and metoprolol, it blocks both beta-1 and beta-2 receptors (it is "nonselective") and also blocks alpha-1 receptors on blood vessels, so it can lower blood pressure more when standing than when lying down. The liver breaks it down, mainly through the enzymes CYP2D6 and CYP2C9, so some other medicines can raise or lower its level.
Is it worth it for you?
Use this as a quick fit check, not a diagnosis.
Worth considering if…
Probably skip if…
Evidence at a glance
| Goal | Effect | Best fit | Time |
|---|---|---|---|
survival in mild to moderate heart failure Good Evidence | 65 percent lower risk of death over 6 to 12 months (3.2 versus 7.8 percent) | Adults with symptomatic heart failure and an ejection fraction of 35 percent or less, on standard treatment | Within months |
survival in severe heart failure Good Evidence | 35 percent lower risk of death over about 10 months | Adults with severe but stable heart failure and an ejection fraction below 25 percent | Within months |
survival compared with metoprolol tartrate in heart failure Good Evidence | 17 percent lower risk of death than metoprolol tartrate over about 5 years | Adults with heart failure with reduced ejection fraction choosing among beta-blockers with their prescriber | Assessed over a mean of 58 months |
survival after a heart attack with reduced heart function Limited Evidence | 23 percent lower risk of death (12 versus 15 percent); the combined main endpoint was not significantly reduced | Adults after a heart attack with an ejection fraction of 40 percent or less whose condition is stable | Over about a year of follow-up |
survival in mild to moderate heart failure
- Effect
- 65 percent lower risk of death over 6 to 12 months (3.2 versus 7.8 percent)
- Best fit
- Adults with symptomatic heart failure and an ejection fraction of 35 percent or less, on standard treatment
- Time
- Within months
survival in severe heart failure
- Effect
- 35 percent lower risk of death over about 10 months
- Best fit
- Adults with severe but stable heart failure and an ejection fraction below 25 percent
- Time
- Within months
survival compared with metoprolol tartrate in heart failure
- Effect
- 17 percent lower risk of death than metoprolol tartrate over about 5 years
- Best fit
- Adults with heart failure with reduced ejection fraction choosing among beta-blockers with their prescriber
- Time
- Assessed over a mean of 58 months
survival after a heart attack with reduced heart function
- Effect
- 23 percent lower risk of death (12 versus 15 percent); the combined main endpoint was not significantly reduced
- Best fit
- Adults after a heart attack with an ejection fraction of 40 percent or less whose condition is stable
- Time
- Over about a year of follow-up
Evidence for 4 uses
AI-assisted evidence assessment. Talk to your doctor before relying on any single supplement.
survival in mild to moderate heart failure
Disease adjunctThe U.S. Carvedilol Heart Failure program enrolled 1,094 people with chronic heart failure and an ejection fraction of 35 percent or less, already on digoxin, diuretics and an ACE inhibitor, and randomized them to carvedilol or placebo for 6 to 12 months. Deaths were 3.2 percent on carvedilol versus 7.8 percent on placebo, a 65 percent lower risk, and hospital stays for heart causes fell by 27 percent. The program was stopped early because of this difference. The label notes that death was not a primary endpoint of the individual trials, so the numbers need cautious reading, and later larger trials (below) confirmed a survival benefit.
Bottom line: In a large trial program, carvedilol cut deaths sharply in heart failure with a weak heart muscle.
survival in severe heart failure
Disease adjunctCOPERNICUS randomized 2,289 people with heart failure symptoms at rest or on minimal exertion and an ejection fraction below 25 percent, stable and without marked fluid retention, to carvedilol or placebo on top of standard treatment for a mean of 10.4 months. There were 130 deaths on carvedilol versus 190 on placebo, a 35 percent lower risk, and the combined risk of death or hospital stay fell by 24 percent. Fewer people on carvedilol than on placebo withdrew because of side effects or for other reasons. People needing intensive care, intravenous heart drugs or with marked fluid retention were excluded.
Bottom line: Carvedilol lowered deaths by about a third even in severe, stable heart failure.
survival compared with metoprolol tartrate in heart failure
Disease adjunctCOMET randomized 3,029 people with chronic heart failure (NYHA class II to IV, ejection fraction below 35 percent) to carvedilol (target 25 mg twice daily) or immediate-release metoprolol tartrate (target 50 mg twice daily) for a mean of 58 months. Deaths were 34 percent on carvedilol versus 40 percent on metoprolol tartrate (hazard ratio 0.83); the combined rate of death or any hospital admission did not differ significantly (74 versus 76 percent). The comparison used metoprolol tartrate at a modest dose, not the extended-release metoprolol succinate proven in heart failure, so it does not show carvedilol is better than every beta-blocker used for heart failure.
Bottom line: In one long trial, carvedilol lowered deaths more than immediate-release metoprolol tartrate.
survival after a heart attack with reduced heart function
Disease adjunctCAPRICORN randomized 1,959 people who had a confirmed heart attack and an ejection fraction of 40 percent or less, already on modern treatment including ACE inhibitors, to carvedilol (raised to 25 mg twice daily) or placebo. The trial's main endpoint, death or hospital admission for heart causes, was not significantly lower (35 versus 37 percent). Deaths from any cause alone were lower: 12 percent on carvedilol versus 15 percent on placebo (hazard ratio 0.77), along with fewer heart deaths and repeat heart attacks. The FDA label bases the post-heart-attack indication on this trial.
Bottom line: After a heart attack with a weakened heart, carvedilol lowered deaths in one trial, though its main combined goal was missed.
How it works
How to take it
What to track
Bottom line: A prescriber sets and raises the dose slowly. Take it with food, never stop it suddenly, and check new antidepressants, heart drugs, CBD and St. John's wort with your pharmacist.
Safety
Know the common side effects, key cautions, and who should avoid it.
Common side effects
Serious risks
Stopping suddenly: severe worsening of angina, heart attacks and dangerous heart rhythms have been reported after abrupt stopping of beta-blockers in people with angina. The label says to stop it over 1 to 2 weeks whenever possible, and that it may be prudent not to stop it abruptly even in people treated only for high blood pressure or heart failure. (The current Coreg label lists this as a warning, not a boxed warning.)
Low blood pressure and fainting: in heart failure trials, low or postural blood pressure occurred in 9.7 percent and fainting in 3.4 percent on carvedilol versus 3.6 and 2.5 percent on placebo, most often in the first 30 days while the dose was raised
Slow heart rate (about 2 percent in high blood pressure trials, 9 percent in heart failure and 6.5 percent after a heart attack) and worsening heart failure or fluid retention while the dose is being raised
Blood sugar: beta-blockers can hide warning signs of low blood sugar and raise the risk of severe or prolonged lows, especially with diabetes, in children and in anyone fasting or vomiting; in people with heart failure and diabetes, carvedilol may also raise blood sugar
Rare worsening of kidney function in people with heart failure, mainly with low blood pressure, artery disease or existing kidney problems; it returned to baseline when carvedilol was stopped
Other label warnings: bronchospasm in people with lung disease; severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) and angioedema reported after marketing; masking of an overactive thyroid; stronger allergic reactions that may not respond to usual epinephrine doses; and floppy iris syndrome during cataract surgery, so tell your eye surgeon you take it
Who should avoid it
- People with bronchial asthma or related bronchospastic conditions: contraindicated
- People with second- or third-degree heart block, sick sinus syndrome, or severe bradycardia without a permanent pacemaker: contraindicated
- People in cardiogenic shock or with decompensated heart failure needing intravenous inotropic drugs: contraindicated until weaned off those drugs
- People with severe liver impairment, or a history of a serious hypersensitivity reaction to carvedilol: contraindicated
- People with a pheochromocytoma, unless an alpha-blocker has been started first
Pregnancy & breastfeeding
Pregnancy: the label says available data are not enough to know whether carvedilol raises the risk of birth defects or other harm, and that poorly controlled high blood pressure in pregnancy carries its own risks. Beta-blockers used in the third trimester may cause low blood pressure, a slow heart rate, low blood sugar and breathing problems in the newborn, so babies should be watched after birth. Breastfeeding: there are no data on carvedilol in human milk or its effects on a breastfed baby; it is present in the milk of rats, and the label asks that the benefits of breastfeeding be weighed with the mother's need for the drug. If you are pregnant, planning a pregnancy or breastfeeding, talk to your doctor.
Interactions
Energy drinks push blood pressure up, the opposite of what carvedilol does. In a crossover trial in 34 healthy young adults, drinking 32 oz of an energy drink within an hour raised blood pressure and lengthened the QTc interval of the heart rhythm more than placebo (up to about 18 to 20 ms versus 12 ms); the rise in heart rate was no larger than with placebo. No study has tested energy drinks in people taking carvedilol; one case report described a young woman on bisoprolol, another beta-blocker, who drank several energy drinks a day and had a fast heart rhythm that was hard to correct. Avoiding them is the cautious choice, especially with heart failure; review your caffeine use with your doctor or pharmacist.
These drugs also slow the heart. The label says digoxin with carvedilol raises the risk of a slow heart rate and digoxin levels rise by about 15 percent, so digoxin should be monitored more closely; conduction problems have been seen with diltiazem; and with clonidine, carvedilol should be stopped first, with clonidine tapered several days later. Your prescriber plans and monitors these combinations.
St. John's wort speeds up drug-clearing enzymes: in 12 healthy volunteers, 14 days of it doubled the clearance of alprazolam through CYP3A4, though it did not change CYP2D6 activity. The Coreg label says carvedilol is cleared mainly by CYP2D6 and CYP2C9 and to a lesser extent CYP3A4, and that rifampin, a strong enzyme inducer, cut carvedilol levels by about 70 percent. No study has measured St. John's wort with carvedilol, so the size of any effect is unknown. Tell your prescriber before starting or stopping it, since a change in either direction could shift your blood pressure and heart rate.
In human liver enzyme studies, CBD was a potent blocker of CYP2D6, and the Coreg label says CYP2D6 blockers are expected to raise levels of the blood-vessel-relaxing form of carvedilol; people with low CYP2D6 activity had more dizziness while the dose was raised. Whether everyday CBD doses do this in people has not been tested. A single 600 mg dose of CBD also lowered resting systolic blood pressure by about 6 mmHg in 9 healthy men. Tell your prescriber if you use CBD and watch for dizziness, fainting or an unusually slow pulse.
In a 4-week randomized crossover trial in 52 people with high blood pressure, celery seed extract capsules (1.34 g a day) lowered 24-hour systolic pressure from 141.2 to 130.0 mmHg, with no change on placebo; celery juice itself has not been tested. Regular use could add to carvedilol's blood pressure lowering, which already makes dizziness on standing common. Check your home readings, watch for dizziness on standing, and review it with your doctor or pharmacist.
The label says strong CYP2D6 blockers have not been studied but are expected to raise carvedilol levels, and that amiodarone at least doubled levels of the beta-blocking form, which can slow the heart further or cause heart block; it names fluconazole as another CYP2C9 blocker with the same concern. Ask your pharmacist to check any new antidepressant, antifungal or heart rhythm medicine.
In 21 kidney transplant patients, starting carvedilol raised cyclosporine levels modestly; about 30 percent needed a lower cyclosporine dose, about 20 percent lower on average. The label advises close monitoring of cyclosporine levels after carvedilol is started, so make sure your transplant team knows.
Documented interactions
Evidence-graded pair pages with sources, dosing notes, and timing guidance, a complement to the narrative section above.
See all 1 Carvedilol interaction →Choosing a product
What to look for on the label, and what to be skeptical of.
Look for…
Be skeptical of…
Frequently asked questions
Can I take St. John's wort with carvedilol?⌄
It has not been studied with carvedilol, but St. John's wort speeds up the enzymes that clear many drugs, and the carvedilol label shows that rifampin, a strong enzyme inducer, cut carvedilol levels by about 70 percent. Talk with your prescriber before starting it, and if you already take both, ask your prescriber before stopping it, since a change in either direction could shift your blood pressure and pulse.
Is CBD safe with carvedilol?⌄
It is not proven safe or unsafe. In lab studies CBD strongly blocks CYP2D6, one of the enzymes that clears carvedilol, and the label says blockers of that enzyme are expected to raise carvedilol levels, which can add to dizziness. CBD can also lower blood pressure a little. Tell your prescriber if you use it and report dizziness, fainting or an unusually slow pulse.
Can I drink energy drinks or coffee while taking carvedilol?⌄
Energy drinks are best avoided: in a trial of healthy young adults, a large energy drink raised blood pressure and changed the heart's electrical rhythm. Carvedilol itself has not been tested with energy drinks. Talk with your doctor or pharmacist about how much caffeine is reasonable for you, especially if you have heart failure.
Why do I have to take carvedilol with food?⌄
The label says food slows how fast carvedilol is absorbed without lowering the total amount, which reduces the drop in blood pressure on standing that can cause dizziness or fainting. This matters most when you start or your dose goes up. Coreg CR capsules are taken once daily in the morning with food.
Why does my dose go up so slowly?⌄
In heart failure, carvedilol is started at a low dose and raised every 2 weeks or more because fluid retention, low blood pressure and dizziness are most likely while the dose changes. The label says these episodes can usually be managed without stopping and do not prevent a good long-term response. Your prescriber decides each step.
Can I stop carvedilol if I feel fine?⌄
Do not stop it on your own. The label warns that stopping a beta-blocker suddenly has caused severe chest pain, heart attacks and dangerous heart rhythms in people with heart artery disease, and says carvedilol should be stopped over 1 to 2 weeks when possible, and that it may be prudent not to stop it abruptly even in people taking it for blood pressure or heart failure. Your prescriber will plan any change.
References by claim
survival in mild to moderate heart failure
Packer et al., 1996 · PubMed (1996) link
survival in severe heart failure
Packer et al., 2001 · PubMed (2001) link
survival after a heart attack with reduced heart function
Dargie et al., 2001 · PubMed (2001) link
survival compared with metoprolol tartrate in heart failure
Poole-Wilson et al., 2003 · PubMed (2003) link
Safety
Coreg (carvedilol) tablets prescribing information · DailyMed (FDA label) link
Interaction: Energy drinks
Interaction: St. John's wort
Markowitz et al., 2003 · PubMed (2003) link
Interaction: CBD (cannabidiol)
Interaction: Celery juice and celery seed extract
Shayani Rad et al., 2022 · PubMed (2022) link
Track Carvedilol with Pilora
Set up dose reminders, check interactions, and join the community in the Pilora app.
Disclaimer: This page summarizes published clinical-trial data for educational purposes and is not medical advice or a recommendation to use this prescription medication. Dosing, eligibility, and monitoring must be decided by a licensed prescriber.
